CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination and poor prognosis. We evaluated the novel CXCR4 probe [ + flow cytometry did not reveal significant blood count changes associated with tracer application. Based on these highly encouraging data on clinical PET imaging of CXCR4 expression in a cohort of MM patients, we conclude that [
Introduction
Chemokine receptor-4 (CXCR4) is a member of the G-proteincoupled chemokine receptor family. The sole known natural ligand of CXCR4 is CXCL12/SDF-1. SDF-1 binding to CXCR4 activates downstream signaling pathways such as MAP kinase and the PI3 kinase pathway, ultimately resulting in altered cell adhesion, migration, and homing (Zlotnik et al, 2011; . CXCR4 is normally expressed on T and B lymphocytes, monocytes, macrophages, neutrophils, and eosinophils, and by hematopoietic stem/progenitor cells (HSPCs) residing within the bone marrow (BM) niche. Antagonizing the CXCR4-mediated retention of HPCs in this niche by means of anti-CXCR4-directed treatment with the CXCR4 antagonist plerixafor allows mobilization of HPCs for autografting upon myeloablative therapies (Brave et al, 2010) . Plerixafor treatment also mobilizes various lymphocyte populations into the peripheral blood, emphasizing the important role of the SDF-1/ CXCR4 axis for lymphocyte trafficking (Kean et al, 2011) .
Pathological CXCR4 overexpression has been reported in various types of solid cancers and in hematopoietic malignancies such as leukemia and lymphoproliferative malignancies (Burger & Peled, 2009; Cojoc et al, 2013) . In cancer, CXCR4 overexpression and receptor activation by SDF-1 binding are key triggers for tumor growth and progression, invasiveness, and metastasis (Muller et al, 2001) . Accordingly, CXCR4 overexpression has been identified as an adverse prognostic factor in various malignancies (Spano et al, 2004; Spoo et al, 2007) . In particular, CXCR4-mediated interaction that holds cancer (re-)initiating cells within a protective tumor microenvironment (TME) seems to be responsible for resistance to pharmacological treatment, and for relapse, at least in hematopoietic cancers (Teicher & Fricker, 2010; Mendelson & Frenette, 2014; Shain & Tao, 2014) .
Multiple myeloma (MM, plasma cell myeloma) is the second most prevalent B-cell cancer. Despite the availability of potent novel drugs, it remains, for the large part of patients, an incurable disease (Palumbo & Anderson, 2011; Ocio et al, 2014) . MM is characterized by the expansion of malignant plasma cells predominantly within the BM. One key clinical characteristic is the uncoupling of bone formation and bone destruction, resulting in osteolytic bone lesions (Raab et al, 2009; Roodman, 2010) . Studies on both cultured and patients' primary MM cells showed a strong correlation between CXCR4/SDF-1 activation and MM-related bone disease (Zannettino et al, 2005; Bao et al, 2013) . SDF-1 engages CXCR4 on MM cells favoring their recruitment to the BM by affecting migration, adhesion, and extravasation (ParmoCabanas et al, 2004; Aggarwal et al, 2006; Alsayed et al, 2007) . Besides the different cell types constituting the BM niche, primary MM cells themselves secrete SDF-1, which results in autocrine stimulation of plasma cell proliferation. Therefore, the CXCR4/SDF-1 axis represents a highly relevant molecular target in MM and other cancers due to its important role in pathogenesis and its potential involvement as a mediator of resistance to treatment (Burger & Kipps, 2006) .
Despite the fundamental role of CXCR4 in cancer and in particular MM biology and its significance as a target for therapeutic approaches, a highly sensitive method for CXCR4 assessment and quantification in vivo has been lacking so far. Such in vivo assessment of CXCR4 expression could provide an additional and clinically important method to select patients for CXCR4-directed treatment, for example, by anti-CXCR4 antibodies that are in early-phase clinical trials (Kashyap et al, 2012) .2), a highaffinity CXCR4-targeted nuclear probe for PET imaging, has recently been developed Gourni et al, 2011) and evaluated in a first proof-of-concept investigation (Wester et al, 2015) . The present study aimed at the evaluation of [ 68 Ga]Pentixafor PET/CT as a novel and powerful tool for sensitive, non-invasive in vivo quantification of CXCR4 in preclinical models of MM and in a clinical pilot assessment investigating patients with advanced MM.
Results

Frequency of MM patients with high tumor CXCR4 (CD184) expression
The CXCR4-SDF-1 axis constitutes a central mechanism for recruiting and retaining MM cells within the TME (Zannettino et al, 2005; Bao et al, 2013) . To investigate the frequency of MM patients with high CXCR4 expression, we performed flow cytometry on an unselected cohort of 25 patients undergoing BM biopsy for previously established MM, or because of newly diagnosed monoclonal gammopathy. By assessing CXCR4 expression as compared to an isotype control antibody (gating strategy depicted in Supplementary Fig S1) , we identified 14 of 25 patients (56%) with CXCR4-positive MM. Representative histograms depicting CXCR4 + vs. CXCR4 À MM are shown in Fig 1A .
In order to estimate the magnitude of CXCR4 expression in MM cells compared to normal non-malignant cell populations that have previously been described as CXCR4 positive (Aiuti et al, 1999; Honczarenko et al, 1999; Burger & Kipps, 2006; Brave et al, 2010) , we compared CXCR4 expression levels in individual MM patient samples judged CXCR4 positive by flow cytometric and immunohistochemical assessment (CXCR4 + MM).
In CXCR4 + MM, relative plasma cell surface CXCR4 expression levels were significantly higher than those on intraindividual CD19 + B cells, CD3 + T cells, CD34 + HSPCs, and CD14 + monocytes (Fig 1B-D ; gating strategy depicted in Supplementary  Fig S1; representative data shown in Supplementary Fig S2A-D) , indicating that a CXCR4-directed PET tracer could be suitable for MM imaging. Thus, in our unselected cohort, over 50% of MM patients expressed CXCR4 on their plasma cells. Relative cancer cell CXCR4 expression in these patients was high compared to intraindividual control BM cell populations. 
MM in vivo
Considering the high CXCR4 expression levels in a substantial proportion of MM patients as compared to intraindividual control cell populations, we searched for MM cell lines that could be suited for preclinical in vivo imaging studies. Considerable levels of CXCR4 transcript (Fig 2A) and protein ( Fig 2B) were detected in the well-established MM lines MM.1S and OPM-2 as opposed to the ovarian cancer cell line HeLA, which is characterized by low CXCR4 expression. Moreover, MM.1S and OPM-2 cells were found to bind the CXCR4-directed PET probe [
68 Ga]Pentixafor (Fig 2C) . Thus, these cell lines represent models for in vivo binding and uptake studies. In order to determine the suitability of the high-affinity human CXCR4-specific probe Pentixafor as an in vivo MM PET tracer, NOD SCID mice were xenografted with MM. in the respective xenografts observed in the small animal PET studies (Fig 2F and G) . As expected when using a human CXCR4-specific probe such as Pentixafor , virtually no tracer uptake was observed in CXCR4-expressing mouse organs such as spleen, lung, adrenals, or the BM (Fig 2E) . (Fig 2H, Supplementary Fig S3) .
Thus A Real-time PCR analysis of cxcr4 transcript expression levels in HeLa (negative control) and in MM cell lines MM.1S and OPM-2. Shown is the mean relative expression AE SEM (n = 3 independent experiments). Values are normalized to the expression of ubiquitin (Ub). The asterisk indicates statistically significant differences (HeLa vs MM.1S: P < 0.001; HeLa vs OPM-2: P < 0.0001; Student's t-test). B CXCR4 protein expression assessed by immunoblotting (one representative blot out of 3 is shown).
C Binding of [
68 Ga]Pentixafor to MM.1S and OPM-2 cells after the indicated incubation periods (n = 3 per cell line and time point). Shown is the mean AE SEM. The difference between the OPM-2 groups is statistically significant; *P < 0.0017 (one-way ANOVA). D Mean tumor-to-background ratio (TBR) for [ 
Ga]Pentixafor (Student's t-test).
One-way ANOVA revealed significant differences between the groups; P < 0.0001 (not graphically shown). E Representative [ Fig S7) . No further toxicities were observed during or after [ 68 Ga]Pentixafor application.
Discussion
Our data represent the first study on quantitative PET imaging of CXCR4, a key chemokine receptor involved in leukocyte attraction, hematopoietic stem cell homing, tumorigenesis, and many other processes, in preclinical models of myeloma and in a cohort of patients with advanced MM. High CXCR4 expression has been reported in numerous solid cancers and in various hematopoietic malignancies, including MM (Teicher & Fricker, 2010; Weilbaecher et al, 2011) . Importantly, the level of CXCR4 expression assessed by either transcript or whole-cell protein-level analysis is not necessarily representative of CXCR4 expression level on the cell surface (Teicher & Fricker, 2010) . CXCR4 overexpression on the cell membrane is, however, the key parameter for successful CXCR4-directed tumor targeting in vivo, both for diagnostic imaging and in particular for endoradiotherapeutic approaches. Our in-depth analysis of intraindividual surface CXCR4 levels in BM subpopulations revealed that in at least half of the patients, CXCR4 expression on the surface of MM cells is significantly elevated as compared to B and T cells, monocytes, and CD34 + HSPCs. High levels of CXCR4 have been shown to indicate particularly aggressive disease, metastasis, or poor prognosis in solid cancers (Teicher & Fricker, 2010; Weilbaecher et al, 2011) and AML (Spoo et al, 2007) . Such correlations are, however, not expected in MM, a malignancy that is at primary diagnosis nearly exclusively BM based (Raab et al, 2009; Roodman, 2010; Palumbo & Anderson, 2011; Ocio et al, 2014) . Although CXCR4/SDF-1 activation and MM-related bone disease are clearly associated (Zannettino et al, 2005; Bao et al, 2013) , it is evident that SDF-1 engages CXCR4 on MM cells favoring their recruitment to the BM by affecting migration, adhesion, and extravasation (Parmo-Cabanas et al, 2004; Aggarwal et al, 2006; Alsayed et al, 2007) . Thus, losing the requirement for MM-TME interactions in situations like plasma cell leukemia or in extramedullary relapse could point to a scenario where [ 68 Ga]Pentixafor PET might be inferior to standard [ 18 F]FDG PET, which has proven diagnostic value in extramedullary MM (Bao et al, 2013; Stessman et al, 2013 ). Although we investigated such patients with EMD after allogeneic SCT with both PET tracers, it is to date not clear whether this is the case. Our data, however, suggest a possible complementary benefit when both PET tracers A Number of patients with visual positivity for the indicated PET tracer (total: n = 14). B Number of patients (total n = 14) for whom imaging with [
Ga]Pentixafor PET (Pentixafor, n = 7) was superior, with comparable positivity (comparable, n = 3), and with dual imaging providing complementary visual information (complementary, n = 2).
CT [ 68 Ga]Pentixafor PET/MR MR-T2stir
A C B Figure 5. [
68 Ga]Pentixafor PET/MR images.
A-C Coronal views of [
68 Ga]Pentixafor (A), T2 STIR weighted MRI (B) and CT bone window (C) of a male patient with histologically proven multiple myeloma. The increased [
68 Ga]Pentixafor uptake correlates with the hyperintense T2 STIR signal; however, the myeloma manifestations are underestimated in the corresponding bone window CT. (Brave et al, 2010) . The dosage used for this purpose is 0.24 mg/kg body weight per day, in combination with granulocyte colony-stimulating factor (G-CSF), and usually applied after several days of G-CSF treatment alone. As expected on the basis of the applied amount of Pentixafor (< 20 lg/patient), we did not observe any side effects of In the vast majority of cases, MM presents as a systemic disease with a measurable monoclonal gammopathy that allows following response to treatment and observing the patient for relapse noninvasively (Rajkumar et al, 2011) . Analysis of serum and urine by means of immunofixation allows for the detection of subclinical disease, and low-dose whole-body computed tomography is a powerful tool for the detection of osteolytic lesions which may prompt initiation of radiotherapy planning (Ippolito et al, 2013) .
EMBO Molecular Medicine
Magnetic resonance imaging (MRI) provides more detailed information about BM infiltration and EMD in MM (Baur-Melnyk et al, 2005) , and [ 18 F]FDG PET imaging clearly provides additional information with regard to prognosis and extent of local disease, in particular EMD (Durie et al, 2002; Zamagni et al, 2011; Agarwal et al, 2013) . Both MRI and [ 18 F]FDG PET are, however, not considered a routine procedure required for every patient (Rajkumar et al, 2011) . The purpose of this study was thus not to establish a novel diagnostic PET tracer for MM in particular, but to test the applicability of this molecular probe in a disease with frequent CXCR4 surface expression. More importantly, however, we consider MM a disease where it would be highly interesting to combine [ Ga-labeled Pentixafor as a marker for patient selection and therapy monitoring, and the latter compounds as endoradiotherapeutics. Such an approach has previously been demonstrated in neuroendocrine tumors with resounding success (Breeman et al, 2003; Das et al, 2007; Werner et al, 2014) . The most obvious and attractive scenario would thus follow the sequence [ 68 Ga]Pentixafor PET, therapy with a radionuclide or toxin, a standard myeloablative therapy, followed by SCT. SCT thus would allow applying labeled Pentixafor doses that will most likely result in perturbations of BM function. Such an approach is currently under investigation. Also, disintegrating and targeting the HSC interaction with its BM niche could be an interesting principle in treating HSPC disorders Shain & Tao, 2014) . In addition to such direct usage of Pentixafor as a carrier for active agents, the use as an imaging modality for patient selection would be an obvious approach, for example, for anti-Notch-directed treatments that are currently being evaluated and involve CXCR4-SDF-1 activation (Mirandola et al, 2013) , or for selection of patients receiving anti-CXCR4 therapies such as BMS-936564/MDX-1338, a fully human anti-CXCR4 antibody currently in clinical investigation (Kuhne et al, 2013) .
Our data demonstrate the suitability of [ 68 Ga]Pentixafor for PET imaging of CXCR4 chemokine receptor expression in MM patients. We conclude that this novel PET tracer could serve as an innovative imaging agent, for in vivo biomarker identification that could result in patient selection for CXCR4-directed treatments, and eventually for receptor-radio(drug)peptide therapy.
Materials and Methods
Patients
Detailed characteristics for the PET imaging patient cohort are given in The current study is not a confirmatory one. There were no prespecified hypotheses that would have allowed for sample size calculation. It is an observational pilot study used to conduct explorative analyses. Therefore, the sample size was chosen to serve this purpose. It enabled the computation of descriptive and explorative statistics.
Cell lines and cell culture
The human multiple myeloma cell lines OPM-2 (DSMZ no. ACC50) and MM.1S (ATCC CRL-2974) were cultured in RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 lg/ml streptomycin. HeLa cells were cultured in DMEM supplemented with 10% FCS, 100 U/ml penicillin, and 100 lg/ml streptomycin. Cells were maintained at 37°C in a 5% CO 2 humidified atmosphere. All media and supplements were obtained from Invitrogen (Darmstadt, Germany).
Mice and tumor xenograft experiments
Animal studies were performed in agreement with the Guide for Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) , in compliance with the German law on the protection of animals, and with approval of the responsible regional authorities (Regierung von Unterfranken). NOD.CB17-Prkdc RNA and protein extraction, real-time PCR and immunoblotting RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA synthesis was performed using the Omniscript RT Kit according to the manufacturer's protocol (Qiagen, Hilden, Germany). Real-time PCR was performed using Platinum SYBR-Green qPCR SuperMix-UDG (Invitrogen) on an ABI Prism 7700 (Applied Biosystems). Data analysis was performed by comparing Ct values with a control sample set as 1. Sequences for primers are available upon request. Protein extracts (30 lg per lane) were electrophoretically separated on a SDS-PAGE gel, transferred to membranes (Millipore, Darmstadt, Germany), and blotted with antibodies specific for CXCR4 (clone UMB2; Abcam, Cambridge, UK) and b-actin (clone AC-74; Sigma-Aldrich, Taufkirchen, Germany).
Flow cytometry
White blood cell counts, hemoglobin and platelet counts were measured using an Advia 120 (Siemens, Erlangen, Germany). Blood samples from the patients of the imaging cohort were collected in heparin and filtered. Circulating CD34 + cell counts were assessed in peripheral blood by standardized and certified singleplatform flow cytometry on a Cytomics FC 500 analyzer (Beckman Coulter, Krefeld, Germany) at four different time points. Cells were stained with antibodies to CD34 and CD45 (Stem-Kit IM 3630, clone 581; CD45-ECD, clone J33; Beckman Coulter). Bone marrow samples from an unselected MM patient cohort were collected in heparin tubes and filtered. These analyses were performed upon signed informed consent of all patients to analysis of samples for scientific purposes in an anonymized fashion only. Cell populations of interest were selected by sequential gating using Kaluza Flow Analysis Software (Beckman Coulter). The gating strategy is based on CD45 staining versus side-angle light scatter (SSC) properties as a primary gate to separate CD45-positive lymphocytes, monocytes, and CD45low progenitors from CD45-negative plasma cells. Plasma cells were then identified by CD45/CD38 gating and CD19 negativity. Colored back-gating was used to ensure correct gating of all subpopulations. For statistical data analysis, intensity of the isotype control on each subpopulation was subtracted from the median fluorescence intensity of surface CXCR4 expression in that population. Details on the gating strategy used are given in Supplementary Figs S1 and S2. The following antibodies were used: Beckman Coulter: CD20-ECD (clone B9E9), CD45-ECD (clone J33), CD3-PC5 (clone UCHT1), CD138-PC5 (clone BB4), CD14-PC5 (clone RM052), CD34-FITC (clone 581), CD38-FITC (clone T16), CD19-PC7 (clone J4.119), CD56-PC7 (clone N901), and CD33-PC7 (clone D3HL60.251); BD Pharmingen: CXCR4-PE (clone 12G5).
Surface CXCR4 levels of xenografted human MM cell lines were determined by flow cytometry (BD FACSCalibur, Beckton-Dickinson, Heidelberg, Germany) using an anti-CXCR4-PE antibody (hCD184; clone 12G5; Miltenyi, Bergisch-Gladbach, Germany) according to the manufacturer's instructions. Data were analyzed using CellQuest software (Beckton-Dickinson).
Synthesis of [
68
Ga]Pentixafor
Synthesis of [
68 Ga]Pentixafor was performed at both centers in a fully automated, GMP-compliant procedure using a GRP module (SCINTOMICS GmbH, Germany) equipped with disposable singleuse cassette kits (ABX, Germany), using the method and standardized labeling sequence previously described (Martin et al, 2014 
In vivo CXCR4 imaging of mice
Positron emission tomography scans of xenotransplanted MM.1S and OPM-2 tumors in NOD.CB17-Prkdc scid /NCrHsd mice were performed as previously described (Graf et al, 2014 Corresponding CT low-dose scans for attenuation correction were acquired using a low-dose protocol (20 mAs, 120 keV, a 512 × 512 matrix, 5 mm slice thickness, increment of 30 mm/s, rotation time of 0.5 s, and pitch index of 0.8) including the base of the skull to the proximal thighs. In PET/MR, first a coronal 2-point Dixon 3D volumetric interpolated examination (VIBE) T1 weighted (T1w) MR sequence was performed for generation of attenuation maps as recently published (Drzezga et al, 2012) . In addition, both a coronal T1 TSE (TR/TE 600/8.7, slice thickness 5 mm, matrix 384 × 230) and a T2w STIR (short s inversion recovery) sequence with fat suppression (TR/TE/TI 5,000 ms/56 ms/220 ms, slice thickness 5 mm, matrix 106 × 256) were acquired. Consecutively, PET emission data were acquired in three-dimensional mode with a 200 × 200 matrix with 2-3 min emission time per bed position. After decay and scatter correction, PET data were reconstructed iteratively with attenuation correction using a dedicated software (Siemens Esoft).
PET, CT and MR analysis
All CT and MRI scans were scored by a board-certified radiologist, and all PET scans were scored by a board-certified nuclear medicine physician. All PET scans were interpreted in a binary visual fashion as positive for disease or negative for disease according to the criteria previously described (Zamagni et al, 2011) . Briefly, the presence of focal areas of detectable increased tracer uptake within bones (e.g., more intense than background bone marrow (BM) uptake excluding articular processes, with or without any underlying lesion identified by CT) were rated positive. If the scan was rated as positive, disease manifestations were rated as either intra-and/or extramedullary. Intramedullary disease was then separately assessed for 13 regions including head, spine (cervical, thoracic, lumbar), sacrum, pelvis (left and right), upper (left and right) and lower (left and right) extremities, as well as rib cage (left and right). Involvement of the sternum went along in all patients with rib cage manifestations and was therefore not separately assessed. Semi-quantitative analysis comprised calculation of maximum standardized uptake values (SUV max ) as well as SUV mean by 2D ROIs with a diameter of 1.5 cm around the hottest pixel. Up to 3 lesions were recorded, if subjects presented with more than 3 focal lesions (FL); they were categorized into the subgroup > 3 FL. Lesions in the appendicular skeleton were divided from those in the axial portions. Diffuse BM involvement was considered if the tracer uptake was diffusely increased with a SUV max equal to, or greater than, the uptake in the spleen. The presence of extramedullary disease (EMD), defined as [ 18 F]FDG-avid tissue that, according to CT examination, was not contiguous to bone and arose in soft tissue, was described by location and number of lesion. Paramedullary disease arising from bone was considered as a lesion but not as EMD.
CT and MR scans were read as outlined previously (Angtuaco et al, 2004) . In CT, any osteolytic changes not related to degenerative or other benign changes (e.g., hemangioma) were rated as suspicious for MM. In MR, any focal lesion presenting with low signal intensity on T1w TSE images (signal intensity not higher than surrounding muscle) and high signal intensity on T2-weighted sequences and STIR images were judged as suspicious for MM. For intramedullary disease, the same regions were rated as in PET. In addition, any extramedullary lesions defined by extramedullary softtissue formations were noted.
Immunohistochemistry and immunofluorescence of patient biopsy material
For immunohistochemistry, the following antibodies were used: anti-CD138 mouse (B-A38) monoclonal antibody (Cell Marque, CA, USA) and anti-CXCR4 rabbit polyclonal antibody (Abcam). After deparaffinization and rehydration, the slides were placed in a pressure cooker in 0.01 M citrate buffer (pH 6.0) and were heated for 7 min. Incubation with the different antibodies was carried out overnight at 4°C. Detection was performed with DAKO en vision system according to the manufacturer 0 s protocol. For double immunofluorescence, primary antibodies were detected by incubation with the following secondary antibodies: donkey anti-rabbit conjugated with Dylight 488 (Jackson ImmunoResearch, Suffolk, UK) and donkey anti-mouse conjugated with Cy5 (Jackson ImmunoResearch). After incubation of slides with conjugated secondary antibody for 30 min, slides were counterstained and mounted with mounting medium (Vectashield, Vector laboratories, Burlingame, CA, USA).
Statistical analysis
All statistical tests were performed using SPSS Statistics version 22 (IBM) or GraphPad Prism (GraphPad Software). P-values < 0.05
The paper explained Problem Malignancies of the hematopoietic or lymphoid tissues are mostly considered systemic diseases involving the whole body. Therefore, systemic treatment approaches are applied, for example, classical chemotherapy or novel drugs. Cancer cells evade such potentially effective and curative treatment by localizing to a putative protective niche, from where relapse is thought to occur. The chemokine/ chemokine receptor axis SDF-1alpha/CXCR4 is a major determinant for recruiting cancer cells to this protective niche.
Results
Here, we provide the first evaluation of in vivo CXCR4 imaging in a series of patients with a particular cancer of the lymphoid system, multiple myeloma, using the CXCR4-specific PET tracer Pentixafor in comparison with the clinically established tracer FDG. We identify myeloma manifestations that are positive for CXCR4 uptake and establish the use of an in vivo biomarker imaging technique for future therapeutic/theranostic purposes. Supplementary information for this article is available online:
http://embomolmed.embopress.org
